Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Short Interest Update

Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) was the recipient of a large growth in short interest in January. As of January 15th, there was short interest totalling 655,000 shares, a growth of 41.9% from the December 31st total of 461,600 shares. Based on an average daily volume of 257,000 shares, the short-interest ratio is currently 2.5 days. Currently, 4.0% of the shares of the stock are short sold.

Wall Street Analyst Weigh In

Separately, HC Wainwright reaffirmed a “buy” rating and set a $12.00 price objective on shares of Acurx Pharmaceuticals in a report on Friday, January 10th.

Insider Transactions at Acurx Pharmaceuticals

In related news, CEO David P. Luci acquired 49,261 shares of the company’s stock in a transaction dated Monday, January 6th. The stock was bought at an average cost of $1.01 per share, with a total value of $49,753.61. Following the acquisition, the chief executive officer now owns 1,097,458 shares of the company’s stock, valued at approximately $1,108,432.58. The trade was a 4.70 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 29.60% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Acurx Pharmaceuticals

An institutional investor recently raised its position in Acurx Pharmaceuticals stock. Prospect Financial Services LLC raised its position in Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) by 11.5% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 329,076 shares of the company’s stock after acquiring an additional 34,001 shares during the quarter. Prospect Financial Services LLC owned approximately 1.93% of Acurx Pharmaceuticals worth $268,000 at the end of the most recent quarter. 11.53% of the stock is currently owned by hedge funds and other institutional investors.

Acurx Pharmaceuticals Stock Up 4.0 %

Acurx Pharmaceuticals stock opened at $0.76 on Friday. The company has a market capitalization of $12.93 million, a PE ratio of -0.70 and a beta of -1.71. The firm has a fifty day simple moving average of $0.88 and a two-hundred day simple moving average of $1.63. Acurx Pharmaceuticals has a twelve month low of $0.68 and a twelve month high of $3.77.

Acurx Pharmaceuticals (NASDAQ:ACXP) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.17) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.06. During the same quarter in the previous year, the firm posted ($0.24) earnings per share. As a group, equities analysts expect that Acurx Pharmaceuticals will post -0.89 earnings per share for the current fiscal year.

Acurx Pharmaceuticals Company Profile

Acurx Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections.